Researchers and clinicians recently convened at the American Society of Clinical Oncology (ASCO), the world’s largest cancer conference, where the highly anticipated results of the DESTINY-Breast04 trial were announced. DESTINY-Breast04 is a phase 3 trial that sought to determine if using [fam-] trastuzumab deruxtecan, an anti-HER2-antibody drug conjugate (ADC), was more effective than the standard-of-care treatment […]
Melissa Troester, Ph.D., takes an epidemiological approach to understanding the drivers of breast cancer disparities, and how interventions at different levels are key to making impactful and long-lasting change.
Susan G. Komen brings you a look at exciting, new treatments for breast cancer patients.
Susan G. Komen encourages you to dedicate this October as a time of action, both for yourself and for others.
A World Health Organization report showing breast cancer is now the most common form of cancer among women around the world tells us the disease is still impacting millions of women each year.
The omnibus COVID-19 economic relief and appropriations package included many issues that Susan G. Komen advocates have long been pursuing.
Komen-funded research and updates presented at SABCS show there are new treatment options for breast cancers.
Susan G. Komen virtually gathered leading experts and advocates in academia, philanthropy and industry to address breast cancer disparities.
Dr. Laura Esserman shares how the clinical trials she’s leading are helping to personalize breast cancer care.
Donald McDonell, Ph.D., talks with Komen about his research to create more treatments for metastatic breast cancer.
Immunotherapy, or using the body’s own immune system to defeat cancer, could be a cure for breast cancer.
Susan G. Komen chief scientific advisors discuss COVID-19’s impact on breast cancer research.